Thurston Springer Miller Herd & Titak Inc. Has $4.28 Million Stock Holdings in Johnson & Johnson $JNJ

Thurston Springer Miller Herd & Titak Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 23.2% during the 2nd quarter, HoldingsChannel reports. The firm owned 28,009 shares of the company’s stock after purchasing an additional 5,277 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Johnson & Johnson were worth $4,279,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of JNJ. Highline Wealth Partners LLC raised its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC acquired a new stake in Johnson & Johnson in the first quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson in the 1st quarter valued at $49,000. Finally, Capital A Wealth Management LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at $50,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on JNJ. Citigroup boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, August 21st. UBS Group boosted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Thursday, July 17th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday. Barclays boosted their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Finally, Erste Group Bank raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $176.29.

Johnson & Johnson Stock Down 0.2%

Shares of JNJ stock opened at $178.10 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The firm’s fifty day moving average price is $170.81 and its two-hundred day moving average price is $161.29. The firm has a market capitalization of $428.93 billion, a P/E ratio of 19.05, a PEG ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the business earned $2.82 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.